{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06352528",
            "orgStudyIdInfo": {
                "id": "CA127-1070"
            },
            "organization": {
                "fullName": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment",
            "officialTitle": "A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and Those With Moderate and Severe Hepatic Impairment",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-assess-the-drug-levels-of-repotrectinib-in-healthy-participants-and-participants-with-moderate-and-severe-hepatic-impairment"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT05926232",
                "statusForNctId": "AVAILABLE"
            },
            "startDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-24",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-03",
            "studyFirstSubmitQcDate": "2024-04-03",
            "studyFirstPostDateStruct": {
                "date": "2024-04-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Bristol-Myers Squibb",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function."
        },
        "conditionsModule": {
            "conditions": [
                "Hepatic Impairment",
                "Healthy Volunteers"
            ],
            "keywords": [
                "Hepatic Impairment",
                "Healthy Volunteers",
                "Severe",
                "BMS-986472",
                "Repotrectinib",
                "Liver Diseases",
                "Pharmacokinetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1: Moderate Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Repotrectinib"
                    ]
                },
                {
                    "label": "Group 2: Severe Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Repotrectinib"
                    ]
                },
                {
                    "label": "Group 3: Normal Hepatic Function",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Repotrectinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Repotrectinib",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Group 1: Moderate Hepatic Impairment",
                        "Group 2: Severe Hepatic Impairment",
                        "Group 3: Normal Hepatic Function"
                    ],
                    "otherNames": [
                        "BMS-986472"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax)",
                    "timeFrame": "Days 1 to 11"
                },
                {
                    "measure": "Time of maximum observed plasma concentration (Tmax)",
                    "timeFrame": "Days 1 to 11"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))",
                    "timeFrame": "Days 1 to 11"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))",
                    "timeFrame": "Days 1 to 11"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with Adverse Events (AEs)",
                    "timeFrame": "Up to 28 days following last dose"
                },
                {
                    "measure": "Number of participants with Severe Adverse Events (SAEs)",
                    "timeFrame": "Up to 28 days following last dose"
                },
                {
                    "measure": "Number of participants with physical examination abnormalities",
                    "timeFrame": "Up to Day 11"
                },
                {
                    "measure": "Number of participants with vital sign abnormalities",
                    "timeFrame": "Up to Day 11"
                },
                {
                    "measure": "Number of participants with electrocardiogram (ECG) abnormalities",
                    "timeFrame": "Up to Day 11"
                },
                {
                    "measure": "Number of participants with clinical safety laboratory test abnormalities",
                    "timeFrame": "Up to Day 11"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n- Inclusion Criteria for all Participants (Group 1, Group 2, Group 3):.\n\ni) Adult female (as assigned at birth) not of childbearing potential or male (as assigned at birth) of any race or ethnicity.\n\nii) Must have a body mass index between 18 and 40 kg/m2 (inclusive) and body weight \u2265 50 kg at the time of signing the ICF.\n\n- Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group 1 and Group 2):.\n\ni) Participants have moderate or severe HI or cirrhosis due to chronic hepatic disease and/or prior alcohol use.\n\nii) Participants have moderate (Group 1), or severe (Group 2) HI as defined by Child-Pugh score.\n\n- Inclusion Criteria for a Matched Healthy Participant (Group 3):.\n\ni) Participant must be free of any clinically significant disease that would interfere with the study evaluations.\n\nii) Participant must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions therefrom as agreed by the investigator.\n\niii) Participant must be in good health as determined by past medical history, physical examination, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (eg, hematology, chemistry, and urinalysis) and 12-lead ECGs must be within normal limits or clinically acceptable as judged by the investigator.\n\nExclusion Criteria:\n\n- Exclusion Criteria for all Participants (Group 1, Group 2, and Group 3):.\n\ni) Any major surgery within 4 weeks of the study intervention administration.\n\nii) History of drug abuse within 1 year of study intervention administration.\n\niii) History of alcohol abuse within 1 year of study intervention administration.\n\niv) Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.\n\n- Other protocol-defined Inclusion/Exclusion criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BMS Study Connect Contact http://www.bmsstudyconnect.com/",
                    "role": "CONTACT",
                    "phone": "855-907-3286",
                    "email": "Clinical.Trials@bms.com"
                },
                {
                    "name": "First line of the email MUST contain NCT # and Site #.",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bristol-Myers Squibb",
                    "affiliation": "Bristol-Myers Squibb",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Local Institution - 0006",
                    "status": "WITHDRAWN",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33014-2811",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Panax Clinical Research",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33014",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Robert Perry, Site 0003",
                            "role": "CONTACT",
                            "phone": "305-698-4500"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Local Institution - 0005",
                    "status": "WITHDRAWN",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809-3017",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Orlando Clinical Research Center",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Thomas Marbury, Site 0001",
                            "role": "CONTACT",
                            "phone": "407-257-3462"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Local Institution - 0004",
                    "status": "WITHDRAWN",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Texas Liver Institute",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eric Lawitz, Site 0002",
                            "role": "CONTACT",
                            "phone": "210-253-3426"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "BMS Clinical Trial Information",
                    "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"
                },
                {
                    "label": "FDA Safety Alerts and Recalls",
                    "url": "http://www.fda.gov/MEDWATCH/safety.htm"
                },
                {
                    "label": "BMS Clinical Trial Patient Recruiting",
                    "url": "https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT06352528.html"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "See plan description",
            "accessCriteria": "See plan description",
            "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Hepatic Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}